Clinical Trial Update: A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers [Phase 1]

View source ↗

Summary

A Phase 1 first-in-human study evaluated BAY3630942 after BAY3547922, focusing on distribution, pharmacokinetics, and safety. The trial in hepatocellular carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• BAY3547922
• BAY3630942

Snippet

Sponsor: Bayer | Conditions: Hepatocellular Carcinoma (HCC), Solid Tumors | Phase 1 | Status: COMPLETED